The educational impact of a curriculum for oncologists on the latest developments in the use of CDK4/6 inhibitors in HR+/HER2-early and metastatic breast cancer

被引：0

作者：

Dorkhom, N. ^{[1
]}

Ragoonath-Cameron, D. ^{[2
]}

Bahra, S. ^{[3
]}

Patel, U. ^{[4
]}

Phoenix, V. ^{[4
]}

机构：

[1] Medscape, Medscape Oncol, Naarden, Netherlands

[2] Medscape, Medscape Oncol, Miami, FL USA

[3] Medscape Oncol, Medscape, London, England

[4] Medscape, Medscape Oncol, New York, NY USA

来源：

关键词：

D O I：

10.1016/j.annonc.2022.03.098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

83P

引用

页码：S159 / S160

页数：2